另外的靶向治疗在于能干扰肺癌细胞繁殖过程中的信号通路。
Other targeted therapies interrupt the signals that cause lung cancer cells to multiply, as shown in the highly magnified image here.
肺癌中表皮生长因子受体的突变及对靶向治疗的敏感性。
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
KRAS基因突变在恶性肿瘤组织中频发，可预测非小细胞肺癌分子靶向治疗的疗效和预后，针对RAS基因的分子抑制剂研究仍处于初级阶段。
KRAS mutation frequency in tumor tissue, can be predicted non-small cell lung cancer molecular targeted therapy efficacy and prognosis, and molecular inhibitors of RAS genes is still in its infancy.
对晚期非小细胞肺癌、且不适合或不愿接受放、化疗、靶向治疗患者，是一种行之有效且安全的治疗方法。
For advanced non-small cell lung cancer, not suitable for or unwilling to accept the radiotherapy and chemotherapy, targeted therapy patients, is an effective and safe treatment.
目的：对小细胞肺癌的化疗、放疗、预防性全脑放疗及靶向治疗等方面的进展进行探讨。
OBJECTIVE: To discuss the progress in the chemotherapy, radiotherapy, preventive radiotherapy of whole brain, targeted therapy etc. for small cell lung cancer (SCLC).
分子靶向治疗是肺癌治疗的新方法。
Molecular targeted therapies are new approaches in lung cancer treatment.
本文主要对肺癌的分子靶向治疗研究进展进行概括总结。
This article will summarize the new development of molecular targeted therapies currently in lung cancer.
目的：鉴定抑制肺癌细胞生长的功能性单克隆抗体1E2及其抗原，为治疗肺癌提供有潜力的靶向抗体治疗剂和分子靶位。
Objective: To identify a functional monoclonal antibody 1E2 against lung cancer and its antigen, so as to provide a candidate antibody drug and molecule target for the anti-lung cancer therapy.
研究人员发现，如果用药抑制MET基因的扩增，可以使肺癌靶向治疗的有效率从71%提高到93%。
The researchers found that if the drugs inhibit MET gene amplification will enable the efficient targeted therapy of lung cancer from 71% to 93%.
肺癌分子靶向治疗近年来取得较大进展，特别是针对表皮生长因子受体(EGFR)分子靶向药物表现出确定的临床效果。
Molecular targeted therapy has a advance development, the molecular targeted therapies drug for epidermal growth factor receptor (EGFR) present definite clinic effect.
本项基因治疗策略以直接调控细胞周期的抑癌基因为靶向治疗基因，为肺癌基因治疗提供了可靠的理论依据。
The strategy targeted to the tumor suppressor gene that regulates the cell cycle directly, obtained satisfactory results, and provided a reliable theory for lung cancer gene therapy.
非小细胞肺癌的系统治疗已经由“一刀切”的经典化疗转变为针对特异分子改变的靶向治疗。
The systemic therapy of non-small cell lung cancer (NSCLC) is moving away from the "one-size fits all" empiric chemotherapy to targeted therapy of specific molecular alternations.
目的评价氩氦刀靶向治疗中晚期非小细胞肺癌的生存率和生活质量。
Objective To assess the survival rate and life quality of patients with intermediate and advanced non-small cell lung cancer (NSCLC) after argon-helium cryoablation.
该抗体识别的抗原CPS1可表达于肺癌细胞的细胞膜，可能是一个肺癌靶向治疗的新靶位。
CPS1, the antigen of 1e2, locates on the membrane of lung cancer cells and it may become a novel molecule target for lung caner therapy.
该抗体识别的抗原CPS1可表达于肺癌细胞的细胞膜，可能是一个肺癌靶向治疗的新靶位。
CPS1, the antigen of 1e2, locates on the membrane of lung cancer cells and it may become a novel molecule target for lung caner therapy.
应用推荐